LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit attributable to shareholders was HK$91.938 million, a decrease of 1.2% compared to the previous year. Earnings per share stood at HK15.61 cents. The Board proposed a final dividend of HK2.3 cents per share. According to the announcement, the decline in profit attributable to owners of the company reflects the combined impact of a challenging market environment and increased research and development expenditure, which offset the benefits from revenue growth and reduced selling expenses, leading to the year-on-year decrease in net profit.